Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
|
|
- Francis Wiggins
- 6 years ago
- Views:
Transcription
1 EXPEDITED ORIGINAL ARTICLE KS Chan ST Lai C Chu E Tsui CY Tam L Wong W Tse TL Que JS Peiris J Sung VCW Wong! KY Yuen Key words: Coronavirus; Protease inhibitors; SARS virus; Treatment outcome!!"!"#$!"#$%&'()*+! Hong Kong ed J 2003;9: Department of edicine and Geriatrics, United Christian Hospital, 130 Hip Wo Street, Kwun Tong, Hong Kong KS Chan, RCP, HKA (edicine) C Chu, RCP, HKA (edicine) Department of edicine, Princess argaret Hospital, Laichikok, Hong Kong ST Lai, RCP, HKA (edicine) Hospital Authority of Hong Kong, Hong Kong E Tsui, Soc Sc (Statistics) VCW Wong, RCP, HKA (Community edicine) Department of edicine, Tuen un Hospital, Tsing Chung Koon Road, Tuen un, Hong Kong CY Tam, RCP, HKA (edicine) Department of edicine and Geriatrics, Caritas edical Centre, 111 Wing Hong Street, Shamshuipo, Hong Kong L Wong, RCP, HKA (edicine) W Tse, RCP, HKA (edicine) Department of icrobiology, Tuen un Hospital, Tsing Chung Koon Road, Tuen un, Hong Kong TL Que, RCPath, HKA (Pathology) Department of icrobiology, The University of Hong Kong, Queen ary Hospital, Pokfulam, Hong Kong JS Peiris, D, PhD KY Yuen, D, RCPath Department of edicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong J Sung, D, RCP Correspondence to: Prof KY Yuen ( kyyuen@hkucc.hku.hk) Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study!l!"#$%&'()*+,-./0123!"#$%& Objectives. To investigate the possible benefits and adverse effects of the addition of lopinavir/ritonavir to a standard treatment protocol for the treatment of severe acute respiratory syndrome. Design. Retrospective matched cohort study. Setting. our acute regional hospitals in Hong Kong. Patients and methods. Seventy-five patients with severe acute respiratory syndrome treated with lopinavir/ritonavir in addition to a standard treatment protocol adopted by the Hospital Authority were matched with controls retrieved from the Hospital Authority severe acute respiratory syndrome central database. atching was done with respect to age, sex, the presence of co-morbidities, lactate dehydrogenase level and the use of pulse steroid therapy. The 75 patients treated with lopinavir/ritonavir were divided into two subgroups for analysis: lopinavir/ritonavir as initial treatment, and lopinavir/ritonavir as rescue therapy. These groups were compared with matched cohorts of 634 and 343 patients, respectively. Outcomes including overall death rate, oxygen desaturation, intubation rate, and use of pulse methylprednisolone were reviewed. Results. The addition of lopinavir/ritonavir as initial treatment was associated with a reduction in the overall death rate (2.3%) and intubation rate (0%), when compared with a matched cohort who received standard treatment (15.6% and 11.0% respectively, P) and a lower rate of use of methylprednisolone at a lower mean dose. The subgroup who had received lopinavir/ritonavir as rescue therapy, showed no difference in overall death rate and rates of oxygen desaturation and intubation compared with the matched cohort, and received a higher mean dose of methylprednisolone. Conclusion. The addition of lopinavir/ritonavir to a standard treatment protocol as an initial treatment for severe acute respiratory syndrome appeared to be associated with improved clinical outcome. A randomised double-blind placebocontrolled trial is recommended during future epidemics to further evaluate this treatment.!"#$%&'()*+,-./ :l!"#$%&'!"#$%&'!"#$%&'()*+,-!"#tr!"#l!"#$%&'()*+,-./0123!"#$%&'()*+,-./ !"#789:;!"#$%&'()*+),-!.)/012345%6789:;<=!"#$%&'() TR!"# L!"#$%&'()!*+ L!"#$%&'()*!+,$%-.&/ SPQ PQP!"#$%&'()*+,-./ !"#$%&'()*+,-./0123"#4!" L!"#$%&'()*+,-. OKPB!" B!"#$! NRKSB NNKB mykr!"#$%&' Hong Kong ed J Vol 9 6 December
2 Chan et Introduction Severe acute respiratory syndrome (SARS) has created global alarm, with significant impact on the health care and economy of affected areas. At the time of writing, at least 30 regions had been affected with over 8099 probable cases and 774 deaths. 1 The intubation rate for patients with SARS in many centres was over 20%, 2,3 and the overall case fatality rate was 9.6%. 1 Both human and animal studies have now confirmed that SARS is caused by a novel coronavirus (SARS-CoV), 4-6 satisfying Koch s postulations for causation. 7,8 In the early days of the epidemic, histopathological changes in lung tissue from patients suggested a viral aetiology possibly associated with immuno-dysregulation in pathogenesis as evident by the pronounced activation of macrophages within the alveoli. 9 Various treatment regimens were recommended for SARS, ranging from supportive therapy to intensive immunomodulation by corticosteroids, with the majority being empirical. 2,3,10-12 Before SARS-CoV was identified as the causative agent, ribavirin, a purine nucleoside analogue which prevents replication of a large number of RNA and DNA viruses, was suggested for treatment in view of its broad spectrum activity. 2,13 Based on this theoretical background and the low fatality rate reported in early cases, 2,10 the combination of corticosteroid and ribavirin therapy was adopted by the Hospital Authority of Hong Kong (HA) as the interim standard treatment in the early phase of the SARS epidemic. 14 With isolation of SARS-CoV, in vitro anti-viral susceptibility testing demonstrated that the virus was inhibited by ribavirin at a level which was difficult to achieve in the clinical setting. 15 As the epidemic progressed, the case fatality rate in Hong Kong was projected to be around 13% for patients younger than 60 years and 43% for patients aged 60 years or older, 16 indicating an urgent need to find an effective therapy. A previous prospective study of the clinical progression of SARS and the viral load of patients demonstrated a progressive increase in viral load in the respiratory tract, reaching a peak in the second week of the illness. 17 The results implied a window period of lower viral load during which anti-viral therapy might confer significant clinical benefit. A number of treatment modalities, including antiviral peptides inhibiting viral fusion, anti-sense RNA, and immunomodulators have been suggested. However, these options are not clinically available at the time of writing. Among the licensed anti-viral drugs screened in our laboratory, lopinavir was demonstrated to have clinically relevant in vitro activity against the prototype SARS-CoV HKU39849; synergism was also demonstrated for lopinavir and ribavirin. 15 Given this information, a number of physicians in the HA had used lopinavir/ritonavir (LPV/r) in addition to the standard treatment protocol. This was given either as an initial treatment, or as a rescue treatment after failure of standard treatment, as previous data had suggested patients might have persistently high viral loads. 17 The aim of this study was to analyse retrospectively the outcomes of patients with SARS treated with LPV/r compared with a matched cohort who received standard treatment only. ethods Diagnosis and standard treatment protocol During the epidemic, all SARS patients were admitted to HA hospitals as policy. A modified World Health Organization definition was adopted as the case definition of probable SARS. This included the presence of the following: fever of 38 Ο C or higher; new radiological infiltrates compatible with pneumonia; two of the following: chills, cough, general malaise, physical signs of lung consolidation; and the absence of an alternative diagnosis to explain the clinical presentation. Probable SARS cases were treated according to the principles of the HA SARS guideline. 10,14,18 These included a trial of broad spectrum antibiotics, consisting of a combination of a β-lactam plus a macrolide, or levofloxacin, according to current recommendations. 19 As soon as the diagnosis of SARS was established, ribavirin was given for 10 to 14 days (2.4 g oral loading dose, followed by 1.2 g orally every 8 hours, or 8 mg/kg intravenously every 8 hours, if the patient could not tolerate oral treatment), together with a tailing regimen of corticosteroid therapy for 21 days (starting dose: hydrocortisone mg every 6-8 hours, or methylprednisolone 3 mg/kg/day, depending on severity). 10,14,18 If patients developed increasing shortness of breath, oxygen desaturation, and radiological worsening, pulses of methylprednisolone mg daily given intravenously were used as rescue therapy, if not contraindicated. 10 Patients were considered for intubation if they developed acute respiratory distress syndrome (ARDS) as defined by a partial pressure of arterial oxygen to fraction of inspired oxygen (PaO 2 /io 2 ) ratio of <200 mmhg, 20 or had persistent and severe hypoxaemia with oxygen saturation of less than 85%, despite oxygen supplementation. Lopinavir/ritonavir treatment protocol rom 16 April 2003, physicians from four participating hospitals (United Christian Hospital, Princess argaret Hospital, Tuen un Hospital, and Caritas edical Centre) 400 Hong Kong ed J Vol 9 6 December 2003
3 Treatment of severe acute respiratory syndrome added lopinavir 400 mg/ritonavir 100 mg orally every 12 hours to the above standard regimen after obtaining consent from patients. Patients with contra-indications, such as preexisting liver disease, known hypersensitivity, or who were pregnant were excluded from treatment with LPV/r. Approval for off-license use of LPV/r was obtained from the HA. Lopinavir/ritonavir were given for 10 to 14 days, depending on disease severity and patient tolerance. Physicians either gave LPV/r as an initial treatment in combination with ribavirin for sequential patients newly diagnosed to have SARS; or it was given as rescue therapy later in the course of the illness when patients had worsening oxygen saturation, shortness of breath, and relevant radiological findings, and after patients were judged to have failed pulse steroid treatment. In the latter group, administration of LPV/r may not have been given concurrently with ribavirin, depending on the time of the decision to use LPV/r as rescue therapy. Data collection A standardised data capture form was developed for collecting clinical data for all probable SARS cases admitted to HA hospitals. The information captured included the following: (1) important dates (onset of fever, onset of symptoms, contact with SARS patients, admission, discharge or death); (2) presence of pre-defined co-morbidities (asthma, chronic obstructive pulmonary disease, ischaemic heart disease, cerebrovascular disease, cancer, diabetes mellitus, chronic renal failure, and chronic liver disease); (3) daily observations of clinical parameters (temperature, pulse, respiratory rate, bowel movement, oxygen saturation, fraction of inspired oxygen); and (4) details of drug treatment, invasive and non-invasive ventilation. The clinical information was merged with selected laboratory and pharmacy information from the HA central database. Patients treated with LPV/r who fulfilled the criteria for probable SARS were recruited from the four hospitals. Case matching was performed between the LPV/r-treated group and the HA standard treatment group. Patients treated with LPV/r were divided into two subgroups for analysis: LPV/r as initial treatment and LPV/r as rescue therapy, as previously described. atched cohorts, who were treated with the standard treatment adopted by the HA, were retrieved from the database for the two subgroups. atching was done with respect to the reported prognostic factors for poor outcome: age, sex, presence of co-morbidities and level of lactate dehydrogenase (LDH). 2,3 Age was matched according to five defined age-groups ( years, years, years, years, and 85 years or older). Comorbidity was matched according to the presence or absence of significant medical illnesses. Lactate dehydrogenase was matched according to six defined ranges of LDH levels (<300 IU/L, IU/L, IU/L, IU/L, IU/L, and 900 IU/L). or the subgroup that received LPV/r as initial treatment, matching with patients who received standard treatment was performed on four variables age, sex, comorbidity, and the initial LDH level within 5 days of onset of symptoms. or the subgroup that received LPV/r as rescue therapy after pulse steroid treatment, matching was performed on five variables age, sex, co-morbidity, maximal LDH level before the administration of pulse methylprednisolone, and the use of pulse methylprednisolone. Patients with SARS who had received standard treatment and who matched with the respective study groups on the relevant prognostic variables were included as controls. This approach was adopted to strengthen statistical power and avoid sampling variation due to random selection of control patients from the database. The distribution of patients in the two LPV/rtreated subgroups and their matched cohorts across the prognostic strata are shown in Tables 1a and 1b. The following outcomes were compared for each of the LPV/r-treated subgroups and their matched cohorts: death rate, percentage of patients with oxygen desaturation (inability to maintain normal saturation of 96% despite supplemental oxygen), airway intubation rate, and use of rescue pulse methylprednisolone (proportion and mean dose). Adverse effects in terms of raised serum transaminase levels (a three-fold rise in alanine aminotransferase [ALT]) and a raised serum amylase level (two-fold rise) were compared between the treatment subgroups and matched cohorts. The age-standardised mortality rates for all patients with SARS aged 15 years or older admitted to the HA during the epidemic were retrieved. These were then classified into five cohorts according to their time of symptom onset. We assessed whether there was a general trend towards declining mortality through the epidemic as clinical knowledge, experience and acumen improved. Statistical analysis To adjust for the differing distribution of patients across the prognostic strata between the LPV/r-treated and the standard treatment group, the direct standardisation method was employed to compute the standardised outcome rates for each of the two matched cohorts, which were then compared with the corresponding crude rates of the LPV/r-treated subgroups. The outcome rates for the matched cohorts were weighed against the proportion of LPV/r-treated cases in each prognostic stratum as shown in Tables 1a and 1b. The outcome rates of the LPV/r-treated group were considered to be significantly different from the respective matched cohort s standardised rates if their 95% confidence intervals (95% CIs) did not overlap. The exact 95% CIs for binomial variables were calculated for the LPV/r-treated subgroups whereas the 95% CIs of the directly standardised Hong Kong ed J Vol 9 6 December
4 Chan et al Table 1a. atching of the LPV/r initial treatment group Sex Co-morbidity Age-group (years) irst lactate dehydrogenase result (IU/L) LPV/r as initial treatment. (%) atched cohort. (%) (27.3) 3 (6.8) 7 (15.9) 2 (4.5) 4 (9.1) 3 (6.8) 49 (7.7) 209 (33.0) 65 (10.3) 69 (10.9) 25 (3.9) 13 (2.1) 18 (2.8) 12 (1.9) 1 (0.2) 6 (0.9) 4 (0.6) 4 (0.6) 114 (18.0) 7 (1.1) 2 (0.3) 10 (1.6) (0.6) (4.5) 22 (3.5) ( Overall) 44 ( 100.0) 634(100.0) Table 1b. atching of the LPV/r rescue treatment group* Sex Co-morbidity Age-group (years) irst lactate dehydrogenase result (IU/L) LPV/r as rescue treatment. (%) atched cohort. (%) (12.9) 3 (9.7) 8 (2.3) 3 (0.9) 84 (24.5) 33 (9.6) 16 (4.7) 25 (7.3) 9 (2.6) 27 (7.9) 7 (2.0) 1 (0.3) 3 (0.9) 2 (0.6) 3 (0.9) 1 (0.3) 49 (14.3) 22 (6.4) 20 (5.8) 17 (5.0) 6 (1.7) 6 (1.7) 1 (0.3) ( Overall) 31 ( 100.0) 343(100.0) * All patients received pulse methylprednisolone rates for the matched cohorts were approximated using the method for weighted sums of independent Poisson variables proposed by Dobson et al. 21 Two sample t-tests were used to test the between-group difference in the mean dose of pulse methylprednisolone. Results The initial database included 1521 probable cases of SARS who were admitted into HA hospitals. There were 676 males and 845 females, and the mean age was 42.5 years (standard deviation [SD], 19.5 years). Eighty-one LPV/rtreated patients were identified from the four centres. Of the 81 LPV/r-treated patients, five patients did not have LDH readings at an appropriate time-point and one patient did not have a matched control, and were therefore excluded from the analyses. Data from 75 patients were analysed, and all had microbiological confirmation of SARS- CoV infection by serology or reverse-transcriptase polymerase chain reaction (RT-PCR) tests. Among the 75 patients, LPV/r was given as initial therapy to 44 patients and as rescue therapy to 31 patients. The prognostic profiles of these patients are reported in Table 2. or the subgroup that received LPV/r as initial treatment, a total of 634 patients were retrieved from the standard treatment group as controls after matching on the four variables of age, sex, co-morbidity, and initial LDH level. 402 Hong Kong ed J Vol 9 6 December 2003
5 Treatment of severe acute respiratory syndrome Table 2. Profiles of the two LPV/r-treated subgroups according to prognostic indicators Sex Age (years) Co-morbidity Prognostic factor Lactate dehydrogenase (LDH) level (IU/L)* Data LPV/r as initial treatment, n=44. (%) ale emale 85 < (27.3) 32 (72.7) 21 (47.7) 15 (34.1) 5 (11.4) 2 (4.5) 10 (22.7) 34 (77.3) 29 (65.9) 8 (18.2) 2 (4.5) 5 (11.4) 0 0 LPV/r as rescue treatment, n=31. (%) 13 (41.9) 18 (58.1) 4 (12.9) 18 (58.1) 7 (22.6) 0 3 (9.7) 28 (90.3) 5 (16.1) 9 (29.0) 4 (12.9) 8 (25.8) 4 (12.9) * The LDH level refers to the initial level for the LPV/r as initial treatment group and to the maximal LDH level before pulse methylprednisolone * for the LPV/r as rescue treatment group Table 3. Comparison of outcomes for the group given LPV/r as initial treatment and a matched cohort* Death rate (%) Intubation rate (%) Desaturation rate (SaO2 95%) [%] Proportion requiring pulse methylprednisolone rescue (%) ean pulse methylprednisolone dose (g) LPV/r as initial treatment, n=44 Crude rate or mean (95% CI) 2.3 (0-6.8) ( ) 27.3 ( ) 1.6 ( ) atched cohort, n=634 Standardised rate or mean (95% CI) 15.6 ( ) 11.0 ( ) 84.5 ( ) 55.4 ( ) 3.0 ( ) * atched on age, sex, presence/absence of co-morbidity, and initial lactate dehydrogenase level Standardised based on the percentage distribution of subjects of the treated group across the prognostic strata in Table 1 NS not significant P value NS Table 4. Comparison of outcomes of the group given LPV/r as rescue treatment and a matched cohort* Death rate (%) Intubation rate (%) Desaturation rate (SaO2 95%) [%] ean pulse methylprednisolone dose (g) LPV/r as rescue, n=31 Crude rate or mean (95% CI) 12.9 (0-25.8) 9.7 (0-22.6) 93.5 ( ) 3.8 ( ) atched cohort, n=343 Standardised rate or mean (95% CI) 14.0 ( ) 18.1 ( ) 92.1 ( ) 3.0 ( ) * atched on age, sex, presence/absence of co-morbidity, lactate dehydrogenase level before pulse methylprednisolone, and use of pulse * methylprednisolone Standardised based on the percentage distribution of subjects of the treated group across the prognostic strata in Table 1 NS not significant P value NS NS NS In this control group, 576 (90.9%) patients had positive SARS-CoV serological or RT-PCR tests. Treatment with LPV/r was started at a median of 5.5 days after symptom onset, and one day after the commencement of ribavirin. Of the 44 patients who received LPV/r as initial therapy, 30 patients (68.2%; 95% CI, ) had episodes of oxygen desaturation and 12 patients (27.3%; 95% CI, ) were given pulse methylprednisolone. ne were intubated and one patient died (2.3%; 95% CI, 0-6.8). In the matched cohort, the respective standardised rates for various outcomes were as follows: oxygen desaturation in 84.5% (95% CI, ); use of pulse methylprednisolone in 55.4% (95% CI, ); intubation in 11.0% (95% CI, ); and death in 15.6% (95% CI, ). Comparing the 95% CIs of the LPV/r-treated group and the matched cohort, there was a statistically significant difference evident in the overall death rate and intubation rate, with reductions seen with LPV/r treatment. As shown in Table 3, the mean dose of pulse methylprednisolone in the subgroup who received LPV/r as initial treatment was lower (1.6 g; 95% CI, ) than the matched cohort (3.0 g; 95% CI, ). Regarding drug toxicity as evidenced by a three-fold rise in ALT, there was no significant difference in rate between the group who received LPV/r as initial therapy and the matched cohort (9.1%; 95% CI, versus 6.9%; 95% CI, ). Raised serum amylase levels (a two-fold rise) were reported in 5% (95% CI, 0-15) in the group given LPV/r as initial treatment compared Hong Kong ed J Vol 9 6 December
6 Chan et al with 2.4% (95% CI, 0-4.8) of the matched cohort (nonsignificant). patient in either group had serum amylase levels greater than 1000 IU/L. or the LPV/r rescue subgroup, a total of 343 patients were retrieved from the standard treatment group as controls after matching of the five variables of age, sex, comorbidity, peak LDH level, and the use of pulse methylprednisolone. In this control group, 329 (95.6%) patients had positive SARS-CoV serological or RT-PCR tests. Treatment with LPV/r was started at a median of 18 days after symptom onset, and did not overlap with ribavirin treatment (median time-lag, 1 day). As shown in Table 4, there were no significant differences in overall oxygen desaturation, intubation, and death rates between the treatment and control groups. The mean dose of pulse methylprednisolone given was significantly higher (3.8 g; 95% CI, ) compared with the matched cohort (3.0 g; 95% CI, ). Regarding drug toxicity as evidenced by a three-fold rise in ALT, there was no significant difference between the group receiving LPV/r as rescue therapy and the matched cohort (25.8%; 95% CI, versus 9.1%; 95% CI, ). Raised serum amylase levels (two-fold rise) were reported in 11.8 % (95% CI, ) in the LPV/r as rescue treatment group versus 2.6% (95% CI, 0-6) of the matched cohort (not significant). In the LPV/r as rescue therapy group, one patient was reported to have a serum amylase level greater than 1000 IU/L, but none was reported in the matched controls. Treatment with LPV/r was discontinued in this affected patient, with subsequent normalisation of amylase levels. The age-standardised mortality rates for 1667 SARS cases aged 15 or more were retrieved from the HA SARS central database. The rates are reported for the five time periods according to the dates of symptom onset: 15.0% for 15 arch 2003 or before; 18.1% for 16 to 31 arch; 17.8% for 1 to 15 April; 15.1% for 16 to 30 April; and 20.8% for 1 to 31 ay. These age-standardised mortality rates did not suggest a trend towards declining mortality throughout the epidemic. Discussion Genomic analysis of the SARS-associated coronavirus genome revealed dfferent types of enzymatic targets the RNA replicase, and the proteases The discovery of a putative mrna cap-1 methyltransferase may suggest another potential target for anti-viral therapy. 25 Although a chemically synthesised cysteine proteinase inhibitor (E64d), 26 a natural salivary cysteine proteinase inhibitor (cystatin D), 27 and a natural serine proteinase inhibitor (leupeptin) 28 are known to inhibit mouse or human coronaviruses in cell culture systems at low concentrations, none of these has been used in the treatment of coronavirus infection in animals or humans. With respect to nucleoside analogues, success has been achieved by ribavirin in treating fulminant hepatitis caused by mouse coronavirus. 29 Ribavirin is active against mouse coronavirus, mostly due to its indirect immunomodulatory effect rather than its weak anti-viral activity. 29 The only anti-viral agent that has been used against coronavirus in human is alpha-interferon, which is given intranasally as a prophylaxis rather than a treatment for common cold. 30 Recently, alpha-interferon and betainterferon have been shown to inhibit SARS-CoV in vitro. 31 Hitherto, alpha-interferon has not been used in the treatment of SARS because it is known to be proinflammatory and associated with pulmonary toxicity, including causing interstitial pneumonitis, and bronchiolitis obliterans-organising pneumonia. 32 Glycyrrhizin, an active component of liquorice root, has been found to inhibit SARS-CoV replication in vitro, 33 but no clinical data are available on its use. Both lopinavir and ribavirin individually have a weak in vitro inhibitory effect on the prototype SARS- CoV. In vitro anti-viral susceptibility testing showed that the cytopathic effect (CPE) of SARS-CoV was inhibited by lopinavir at 4 µg/ml and by ribavirin at 50 µg/ml after 48 hours of incubation. 15 This is in keeping with the fact that lopinavir is specific for aspartate proteases. 34 Using the checkerboard assay for synergy, CPE inhibition was achieved down to a concentration of lopinavir 1 µg/ml plus ribavirin 6.25 µg/ml when the viral inoculum was reduced below 50 TCID 50 (tissue culture infectious dose). 15 Thus, both peak (9.6 µg/ml) and trough (5.5 µg/ml) 35 serum concentrations of lopinavir may inhibit this virus. Synergism between lopinavir and ribavirin might be a reason for the relatively large therapeutic benefits seen in this study, despite the weak anti-viral activities of the individual drugs. Ritonavir has little in vitro activity against SARS-CoV, but it inhibits the CYP3A-mediated metabolism of lopinavir, thereby increasing the serum drug concentration of lopinavir. Our results showed that early use of lopinavir/ritonavir with ribavirin was associated with a reduced use of pulse methylprednisolone, and a reduction in intubation and mortality rates. They also showed that this treatment was not associated with abnormal liver function or with raised serum amylase levels. These benefits were not evident in those patients who received LPV/r rescue therapy, initiated later in the course of the disease when patients had deteriorated further. It is also noteworthy that patients who received LPV/r as rescue treatment received higher doses of pulse corticosteroid, suggesting that physicians had selected patients for LPV/r rescue therapy who were in poorer clinical condition. This might have masked any possible benefits of LPV/r treatment. urthermore, any benefit from synergism between the two anti-viral agents might have been eliminated in the rescue treatment group since ribavirin was already discontinued when LPV/r was added. 404 Hong Kong ed J Vol 9 6 December 2003
7 Treatment of severe acute respiratory syndrome A previous study on the sequential changes in viral load and disease progression of SARS suggested that there was an initial viral replicative phase that led to a maximal viral load at around day 10. Thereafter, the disease progressed to ARDS and severe end-organ damage in some patients. 11 This suggests that in the treatment of SARS, a reasonable strategy is to reduce the peak viral load by an effective antiviral agent, as this might decrease the need for salvage therapy with immunosuppressants, and hence reduce the risk of nosocomial infections. 36 Our results are in keeping with this hypothesis, showing that early use (median, 5.5 days after symptom onset, ie before peak viral replication at day 10), but not rescue use of LPV/r (median, 18 days after symptom onset), was beneficial in terms of reduction in use of pulse corticosteroid therapy, rates of intubation and death. Our study was limited in being retrospective, with patients not randomly assigned to treatment and control groups. Attempts were made to match all the known prognostic factors for the LPV/r-treated subgroups and the controls, however. It is noteworthy that co-morbidities were not classified according to severity, as this may have confounded results. Physicians had possibly selected sicker patients for LPV/r as rescue treatment, as the mean dose of pulse steroid received prior to LPV/r was higher for this group than the matched cohort. This might have masked some of the possible benefits of LPV/r. It is also possible that the apparent benefits of LPV/r seen were due to declining mortality towards the end of the epidemic as clinical experience grew. However, the agestandardised mortality rates were fairly constant throughout the epidemic, arguing against this contention. This study was not designed to evaluate whether ribavirin and/or steroid therapy are effective treatments for SARS. Both the LPV/r-treated and the standard treatment groups were given ribavirin and steroid therapy according to the same standard protocol. uture studies are needed to evaluate these drugs separately. Conclusion The addition of LPV/r to a standard treatment protocol for SARS as an initial treatment appeared to be associated with a significant reduction in the need for rescue pulse corticosteroid therapy, avoidance of intubation, and a reduction in mortality rate. A randomised, double-blind, placebo-controlled trial for the use of anti-viral agents is recommended during future SARS epidemics to fully evaluate this potential treatment. Acknowledgements The authors wish to thank the members of the Hospital Authority SARS Collaborative Group, e-sars Support Team, Informatics Unit, and Statistics and Research Unit for their assistance. References 1. World Health Organization. Summary table of SARS cases by country, 1 vember August WHO website: int/csr/sars/country/en/country2003_08_15.pdf. Accessed 22 September Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J ed 2003;348: Booth C, atukas L, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAA 2003;289: Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361: Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J ed 2003; 348: Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J ed 2003;348: ouchier RA, Kuiken T, Schutten, et al. Aetiology: Koch s postulates fulfilled for SARS virus. Nature 2003;423: Kuiken T, ouchier RA, Schutten, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362: Nicholls J, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361: So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361: Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003;9: Zhong NS, Zeng GQ. Our strategies for fighting severe acute respiratory syndrome (SARS). Am J Respir Crit Care ed 2003;168: Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new trick for an old drug? CAJ 2003;168: Ho W, Hong Kong Hospital Authority Working Group on SARS, Central Committee of Infection Control. Guideline on management of severe acute respiratory syndrome (SARS). Lancet 2003;361: Chu C, Cheng VC, Hung I, et al. The role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. In press. 16. Donnelly CA, Ghani AC, Leung G, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003:361: Peiris JS, Chu C, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361: Severe acute respiratory syndrome. Hong Kong Hospital Authority website: Accessed 22 September Niederman S, andell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care ed 2001;163: Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care ed 1994;149: Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat ed 1991;10: arra A, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003;300: Rota PA, Oberste S, onroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300: Anand K, Ziebuhr J, Wadhwani P, esters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-sars drugs. Science 2003;300: Von Grotthuss, Wyrwicz LS, Rychlewski L. mrna cap-1 methyltransferase in the SARS genome. Cell 2003;113: Hong Kong ed J Vol 9 6 December
8 Chan et al 26. Kim JC, Spence RA, Currier P, Lu X, Denison R. Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d. Virology 1995;208: Collins AR, Grubb A. Cystatin D, a natural salivary cysteine protease inhibitor, inhibits coronavirus replication at its physiologic concentration. Oral icrobiol Immunol 1998;13: Appleyard G, Tisdale. Inhibition of the growth of human coronavirus 229E by leupeptin. J Gen Virol 1985;66: Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TN, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160: Turner RB, elton A, Kosak K, Kelsey DK, eschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 1986;154: Cinatl J, orgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003;362: Kumar KS, Russo W, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97: Cinatl J, orgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003;361: ager PP. The active site of HIV-1 protease. ed Res Rev 2001;21: Hurst, aulds D. Lopinavir. Drugs 2000;60: Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. atal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J ed 2003;349: Hong Kong ed J Vol 9 6 December 2003
Chapter. Severe Acute Respiratory Syndrome (SARS) Outbreak in a University Hospital in Hong Kong. Epidemiology-University Hospital Experience
content Chapter Severe Acute Respiratory Syndrome (SARS) Outbreak in a University Hospital in Hong Kong 3 Nelson Lee, Joseph JY Sung Epidemiology-University Hospital Experience Diagnosis of SARS Clinical
More informationChapter. Background. General Approach. Clinical Outcome. Antiviral Agents. Immunomodulators. Convalescent Plasma. Ventilatory Support.
content Chapter Treatment of Severe Acute Respiratory Syndrome 9 Joseph JY Sung, Alan K Wu Background General Approach Clinical Outcome Antiviral Agents Immunomodulators Convalescent Plasma Ventilatory
More informationClinical Diagnosis & Management of SARS
Clinical Diagnosis & Management of SARS Joseph SUNG MD, PhD Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong Hospital Authority of Hong Kong SAR Diagnosis
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 1.1111/j.1469-691.24.19.x Chronological evolution of,, and neutralisation antibodies after infection with SARS-associated coronavirus P.-R. Hsueh 1,2, L.-M. Huang 3, P.-J. Chen 2, C.-L.
More informationClinical Features and Outcomes of Severe Acute Respiratory Syndrome and Predictive Factors for Acute Respiratory Distress Syndrome
ORIGINAL ARTICLE Clinical Features and Outcomes of Severe Acute Respiratory Syndrome and Predictive Factors for Acute Respiratory Distress Syndrome Cheng-Yu Chen 1,5, Chen-Hsen Lee 5, Cheng-Yi Liu 2,6,
More informationEarly February Surveillance of severe atypical pneumonia in Hospital Authority in Hong Kong. Initiate contacts in Guangdong
SARS: Aetiology JSM Peiris The University of Hong Kong & Queen Mary Hospital WHO SARS Laboratory Network Hospital Authority and Department of Health, HK Early February 2003 Surveillance of severe atypical
More informationNovel Coronavirus 2012
Novel Coronavirus 2012 Susan I. Gerber, MD Respiratory Virus Program Division of Viral Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Jan.
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationSevere acute respiratory syndrome (SARS): breathtaking
Journal of Medical Microbiology (2003), 52, 609 613 DOI 10.1099/jmm.0.05321-0 Review Severe acute respiratory syndrome (SARS): breathtaking progress Peter M. Hawkey, 1 Sanjay Bhagani 2 and Stephen H. Gillespie
More informationAvian Influenza Clinical Picture, Risk profile & Treatment
Avian Influenza Clinical Picture, Risk profile & Treatment Jantjie Taljaard Adult ID Unit Tygerberg Academic Hospital University of Stellenbosch jjt@sun.ac.za 083 419 1452 CLINICAL PICTURE The clinical
More informationMethods ROLE OF OPEN LUNG BIOPSY IN PATIENTS WITH DIFFUSE LUNG INFILTRATES AND ACUTE RESPIRATORY FAILURE
ROLE OF OPEN LUNG BIOPSY IN PATIENTS WITH DIFFUSE LUNG INFILTRATES AND ACUTE RESPIRATORY FAILURE Li-Hui Soh, Chih-Feng Chian, Wen-Lin Su, Horng-Chin Yan, Wann-Cherng Perng, and Chin-Pyng Wu Background
More informationWHO Blood Regulators Network (BRN)
Distribution: General English only WHO Blood Regulators Network (BRN) Position Paper on Collection and Use of Convalescent Plasma or Serum as an Element in Middle East Respiratory Syndrome Coronavirus
More informationNCCID RAPID REVIEW. 1. What are the case definitions and guidelines for surveillance and reporting purposes?
NCCID RAPID REVIEW 1. What are the case definitions and guidelines for surveillance and reporting purposes? Middle East Respiratory Syndrome Coronavirus: Ten Questions and Answers for Canadian Public Health
More informationRenal replacement therapy for patients with diabetes mellitus in Hong Kong
Hong Kong J Journal Nephrol of 2001;3(2):89-96. Nephrology 2001;3(1):89-96. Y CHOY, et al R E N L REGISTRY Renal replacement therapy for patients with diabetes mellitus in Hong Kong o-ying CHOY 1, Yiu-Wing
More informationEpidemiology of SARS in the 2003 Hong Kong epidemic
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES GM Leung 梁卓偉 LM Ho 何禮明 TH Lam 林大慶 AJ Hedley 賀達理 Epidemiology of SARS in the 2003 Hong Kong epidemic Key Messages 1. The temporal and spatial evolution
More informationDiscovery and Development of SARS-CoV 3CL Protease Inhibitors
Discovery and Development of SARS-CoV 3CL Protease Inhibitors Amy K. Patick, Ph.D. Group Director, Head of Virology Pfizer Global Research and Development La Jolla Laboratories http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5212a1.htm
More informationSARS: A new infectious disease for a new century
THEME: Systemic viral infections SARS: A new infectious disease for a new century BACKGROUND A new infectious disease swept the world in early 2003, causing restrictions on international travel and economic
More informationSARS and the Clinical Laboratory
SARS and the Clinical Laboratory Susan M. Poutanen, MD, MPH, FRCPC Microbiologist, Toronto Medical Labs & Mount Sinai Hosp. Infect. Dis. Clinician, University Health Network & Mount Sinai Hosp. Assistant
More informationPharmacologic Treatment of SARS: Current Knowledge and Recommendations
438 Pharmacologic Treatment of SARS Dessmon YH Tai Commentary Pharmacologic Treatment of SARS: Current Knowledge and Recommendations Dessmon YH Tai, 1,2 FAMS (Resp Med), FRCP (Edin), FCCM Abstract The
More informationPublic Health: what is it?
Public Health: what is it? Joseph JY Sung MD, PhD School of Public Health Chinese University of Hong Kong Center for Emerging Infectious Diseases Common Symptoms of SARS 100 90 Mean incubation period
More informationDiagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt?
Eur Respir J 2004; 24: 1025 1032 DOI: 10.1183/09031936.04.00092004 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 REVIEW Diagnosis and pharmacotherapy
More informationOf Camels, Bats and Coronaviruses: the (beginning of the) story of MERS-CoV
Of Camels, Bats and Coronaviruses: the (beginning of the) story of MERS-CoV Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Objectives Discuss the epidemiology, clinical presentation,
More informationZheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.
Title Studies of SARS virus vaccines Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 Issued
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationFatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus
BRIEF REPORT Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus Gabriella A. Farcas, 1,2,4 Susan M. Poutanen, 3,5,7 Tony Mazzulli, 2,3,5,7 Barbara M. Willey,
More informationclinical investigations in critical care
clinical investigations in critical care Clinical and Laboratory Features of Severe Acute Respiratory Syndrome Vis-À-Vis Onset of Fever* Ching-Lung Liu, MD; Yen-Ta Lu, MD, PhD; Meng-Jen Peng, MD; Pei-Jan
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationIdentification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir
Title Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir Author(s) Wong, DKH; Fung, JYY; Lai, CL; Yuen, RMF Citation Hong Kong Medical
More informationPolmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma
Polmoniti: Steroidi sì, no, quando Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma Number of patients Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive
More informationS evere acute respiratory syndrome (SARS) is
373 REVIEW Severe acute respiratory syndrome (SARS): epidemiology and clinical features D S C Hui, M C H Chan, A K Wu, P C Ng... Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease
More informationManeig de les infeccions respiratòries per virus emergents. Antonella Francesca Simonetti Servicio de Enfermedades Infecciosas
Maneig de les infeccions respiratòries per virus emergents Antonella Francesca Simonetti Servicio de Enfermedades Infecciosas Virus respiratorios emergentes Enterovirus D68 MERS-CoV Enterovirus D68 EV
More informationSwine Influenza Update #3. Triage, Assessment, and Care of Patients Presenting with Respiratory Symptoms
Updated 12:00 p.m. April 30, 2009 Swine Influenza Update #3 Introduction: This document revises our last update which was sent April 28 th, 2009. The most important revisions include the following: 1.
More informationSteroids for ARDS. Clinical Problem. Management
Steroids for ARDS James Beck Clinical Problem A 60 year old lady re-presented to ICU with respiratory failure. She had previously been admitted for fluid management and electrolyte correction having presented
More informationA lthough severe acute respiratory syndrome
REVIEW Severe acute respiratory syndrome (SARS) in neonates and children A M Li, P C Ng... Severe acute respiratory syndrome (SARS) runs a more benign course in children during the acute phase. Infants
More informationTreatment of Coccidioidomycosis-associated Eosinophilic Pneumonia with Corticosteroids
Treatment of Coccidioidomycosis-associated Eosinophilic Pneumonia with Corticosteroids Joshua Malo, MD Yuval Raz, MD Linda Snyder, MD Kenneth Knox, MD University of Arizona Medical Center Department of
More informationRepeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia
ORIGINAL ARTICLE Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia Chiung-Zuei Chen, 1 Po-Sheng Fan, 2 Chien-Chung
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationEvolution of the Hospital Capacity for SARS in Taipei
HRC for SARS 26 Evolution of the Hospital Capacity for SARS in Taipei Tzong-Luen Wang, MD, PhD; Kuo-Chih Chen, MD; I-Yin Lin, MD; Chien-Chih Chen, MD; Chun-Chieh Chao, MD; Hang Chang, MD, PhD Abstract
More informationDescription and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
Journal of Medical Microbiology (2003), 52, 715 720 DOI 10.1099/jmm.0.05320-0 Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationAvian Influenza A (H7N9): Clinical Management. KW Choi Associate Consultant IDCTC, HA/ ICB, CHP
Avian Influenza A (H7N9): Clinical Management KW Choi Associate Consultant IDCTC, HA/ ICB, CHP Initial symptoms: nonspecific, similar to most other causes of ILI, CAP High index of suspicion and alertness
More informationARTICLE. Childhood Severe Acute Respiratory Syndrome in Taiwan and How to Differentiate It From Childhood Influenza Infection
ARTICLE Childhood Severe Acute Respiratory Syndrome in Taiwan and How to Differentiate It From Childhood Influenza Infection Luan-Yin Chang, MD, PhD; Fu-Yuan Huang, MD; Yi-Chun Wu, MD, MS; Ih-Jen Su, MD,
More informationRespiratory Syncytial Virus (RSV) in Older Adults: A Hidden Annual Epidemic. Webinar Agenda
Respiratory Syncytial Virus (RSV) in Older Adults: A Hidden Annual Epidemic Wednesday, November 2, 2016 12:00 PM ET Webinar Agenda Agenda Welcome and Introductions William Schaffner, MD, NFID Medical Director
More informationImmunomodulatory Therapy for Severe Influenza
Immunomodulatory Therapy for Severe Influenza Going Beyond Antivirals Patrick Wieruszewski, PharmD PGY2 Critical Care Resident Pharmacy Grand Rounds September 5, 2017 2017 MFMER slide-1 Objectives Review
More informationECMO and the 2013 Influenza A H1N1 Epidemic
ECMO and the 2013 Influenza A H1N1 Epidemic Jonathan Kozinn, MD Department of Cardiac Anesthesiology and Critical Care Why Is an Anesthesiologist Talking About the flu? In susceptible individuals, influenza
More informationMERS CoV Outbreak Riyadh, July-Aug 2015
MERS CoV Outbreak Riyadh, July-Aug 2015 What is MERS-CoV? Middle East Respiratory Syndrome Coronavirus Virus causes severe acute respiratory illness associated with high mortality First identified in Jeddah,
More informationImpact of influenza vaccination on influenza antibody response and unplanned hospital admissions
Impact of influenza vaccination on influenza antibody response and unplanned hospital admissions among community-dwelling Chinese elderly in Hong Kong A randomised controlled trial Dr. L. W. Chu Consultant,
More informationRole of cyclooxygenase-2 in H5N1 viral pathogenesis and the potential use of its inhibitors
Title Role of cyclooxygenase-2 in HN viral pathogenesis and the potential use of its inhibitors Author(s) Lee, MY; Cheung, CY; Peiris, JSM Citation Hong Kong Medical Journal, 2, v. 9 n. Suppl. 4, p. 29-
More informationSevere Acute Respiratory Syndrome ( SARS )
Severe Acute Respiratory Syndrome ( SARS ) Dr. Mohammad Rahim Kadivar Pediatrics Infections Specialist Shiraz University of Medical Sciences Slides Designer: Dr. Ramin Shafieian R. Dadrast What is SARS?
More informationCoronaviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Coronaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Spherical enveloped particles studded with clubbed spikes Diameter 120-160 nm Coiled helical
More informationESMO Preceptorship Program Head & Neck Cancer NPC: Epidemiology, diagnosis and work-up
ESMO Preceptorship Program Head & Neck Cancer NPC: Epidemiology, diagnosis and work-up Dr. John Woo Consultant, ENT Department, PWH Honorary Clinical Professor, Department of Otorhinolaryngology, H&N Surgery
More informationESMO Preceptorship Program Head & Neck Cancer NPC: Epidemiology, diagnosis and work-up
ESMO Preceptorship Program Head & Neck Cancer NPC: Epidemiology, diagnosis and work-up Dr. John Woo Consultant, ENT Department, PWH Honorary Clinical Professor, Department of Otorhinolaryngology, H&N Surgery
More information11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.
The spectrum of pulmonary diseases in HIV-infected persons is broad. HIV-associated Opportunistic infections Neoplasms Miscellaneous conditions Non HIV-associated Antiretroviral therapy (ART)-associated
More informationSupplementary Online Content
Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory
More informationPotential public health impact of RSV vaccines. R. Karron December 2016
Potential public health impact of RSV vaccines R. Karron December 2016 1. RSV is The leading cause of hospitalization in infants and in many high-income countries; >2 million medical visits annually in
More informationImmunogenetics in SARS: a casecontrol
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES MHL Ng 吳香玲 SH Cheng 鄭淑恆 KM Lau 劉建盟 GM Leung 梁卓偉 US Khoo 邱瑋璇 BCW Zee 徐仲鍈 JJY Sung 沈祖堯 Key Messages 1. Human leukocyte antigen (HLA) genotypes from 102
More informationMeta Analysis: Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Meta Analysis: Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? Luke TC, Kilbane EM, Jackson JE, Hoffman SL. Annals of Internal Medicine. 2006 Oct 17;145(8):599-609. Annual Death
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More information2009 (Pandemic) H1N1 Influenza Virus
2009 (Pandemic) H1N1 Influenza Virus September 15, 2009 Olympia, Washington Anthony A Marfin Washington State Department of Health Goals Understand current situation & pattern of transmission of 2009 H1N1
More informationSituation Update Pandemic (H1N1) August 2009
Situation Update Pandemic (H1N1) 2009 31 August 2009 Timeline pandemic (H1N1) 2009 April 12: an outbreak of influenza-like illness in Veracruz, Mexico reported to WHO April 15-17: two cases of the new
More informationSevere Acute Respiratory Syndrome (SARS) Coronavirus
Severe Acute Respiratory Syndrome (SARS) Coronavirus Coronaviruses Coronaviruses are single stranded enveloped RNA viruses that have a helical geometry. Coronaviruses are the largest of RNA viruses with
More informationS evere acute respiratory syndrome (SARS), a contagious
THEORY AND METHODS A simple approximate mathematical model to predict the number of severe acute respiratory syndrome cases and B C K Choi, A W P Pak... See end of article for authors affiliations... Correspondence
More informationPAEDIATRIC RESPIRATORY FAILURE. Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre
PAEDIATRIC RESPIRATORY FAILURE Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre Outline of lecture Bronchiolitis Bronchopulmonary dysplasia Asthma ARDS Bronchiolitis
More informationPneumonia in the Hospitalized
Pneumonia in the Hospitalized Patient: Use of Steroids Nicolette Myers, MD Pulmonary/Sleep/Critical Care November 9, 2018 Park Nicollet Clinic Facts About Pneumonia CAP is the 8 th most common cause of
More informationH1N1 H7N9. Clinical analysis of severe avian influenza H7N9 and severe influenza A H1N1
DOI 10.16047/j.cnki.cn14-1300/r.2018.04.004 2018-05-08 11:56:58 http://kns.cnki.net/kcms/detail/14.1300.r.20180508.1156.008.html 254 Proceeding of Clinical Medicine Apr. 2018 Vol 27 No. 4 J. 2012 13 2
More informationNew viruses causing respiratory tract infections. Eric C.J. Claas
New viruses causing respiratory tract infections Eric C.J. Claas (Re) emerging infectious diseases: what is new? Morens et al. Nature 2004 Virus discovery New molecular methods result in frequent detection
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationDerivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM
Derivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM Ngai Sze WONG 1 ; Tsz Ho KWAN 2 ; Kenny CW CHAN 3 ; Owen TY TSANG 4 ; Man Po
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Bronchiolitis: diagnosis and management of bronchiolitis in children. 1.1 Short title Bronchiolitis in children 2 The remit The
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationSPECTRUM OF DISEASE. Rogelio Perez-Padilla MD National Institute of Respiratory Diseases, Mexico
SPECTRUM OF DISEASE INFLUENZA A H1N1 Rogelio Perez-Padilla MD National Institute of Respiratory Diseases, Mexico DEATHS ARDS PNEUMONIA ILI (fever) Use of health services Respiratory infections (mild) Self-care
More informationRadiographic Features of SARS in Paediatric Patients: A Review of Cases in Singapore
340 Original Article Radiographic Features of SARS in Paediatric Patients: A Review of Cases in Singapore Jaiman V Emmanuel, 1 MBBS, FRCR, Uei Pua, 1 MBBS, FRCR, Gervais KL Wansaicheong, 1 FRCR, M Med,
More informationInfluenza. Giovanni Maciocia
Influenza Giovanni Maciocia Zhang Zhong Jing (about 150-219AD) Ye Tian Shi (1667-1746) Wu Ju Tong (1758-1836) 1. WESTERN MEDICINE VIEW a) INFLUENZA INFLUENZA IN CHINESE MEDICINE Epidemiologists predict
More informationPrevention and treatment of swine-origin influenza virus with interferon: an in vivo and ex vivo study
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Prevention and treatment of swine-origin influenza virus with interferon: an in vivo and ex vivo study JM Nicholls *, RWY Chan, E Fish K e y M e s s
More informationEpidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell
LOWER RESPIRATORY TRACT INFECTIONS Preface Thomas M. File, Jr xiii Community-Acquired Pneumonia: Pathophysiology and Host Factors with Focus on Possible New Approaches to Management of Lower Respiratory
More informationAbstract. Key words. Children; Influenza; Oncology; Pandemic
HK J Paediatr (new series) 2010;15:198-203 Clinical Presentations and Outcome of Hospitalised Paediatric Oncology Patients with Laboratory-confirmed Pandemic H1N1 Influenza Infection in Hong Kong FWT CHENG,
More informationRadiologic Pattern of Disease in Patients with Severe Acute Respiratory Syndrome: The Toronto Experience 1
SPECIAL REPORT 553 Radiologic Pattern of Disease in Patients with Severe Acute Respiratory Syndrome: The Toronto Experience 1 Narinder S. Paul, MD Heidi Roberts, MD Jagdish Butany, MD TaeBong Chung, MD
More informationUpdate of hepa++s E in Hong Kong. Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital
Update of hepa++s E in Hong Kong Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital HEV: The History Probably causing human disease for centuries Iden+fied on EM by Dr Balayan in 1983 Viral
More informationMayo Clin Proc, July 2003, Vol 78 SARS 883 Figure 1. Chain of transmission of severe acute respiratory syndrome from the initial patient to other gues
882 Concise Review for Clinicians SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures PRIYA SAMPATHKUMAR, MD; ZELALEM TEMESGEN, MD; THOMAS F. SMITH, PHD; AND RODNEY L.
More informationTHE PHARMA INNOVATION - JOURNAL Acute exacerbation of chronic obstructive pulmonary disease, caused by viruses: the need of combined antiinfective
Received: 19-11-2013 Accepted: 28-12-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 11. 2014 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION
More information(NIPPV) (SARS) (ARF) SARS NIPPV NIPPV NIPPV SARS ARF 95% (19 / 20) ICU SARS SARS
Thomas M. T. Cheung, FHKAM, MRCP, FCCP; Loretta Y. C. Yam, FHKAM, FRCP, FCCP; Loletta K. Y. So, FHKAM, MRCP; Arthur C. W. Lau, FHKAM, MRCP; Edwin Poon, FHKAM, MRCP; Bernard M. H. Kong, FHKAM, FRCPE, FCCP;
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationNOVEL INFLUENZA A (H1N1) Swine Flu
Introduction Definitions Influenza-like Illness Emergency Department Assessment Anitiviral Medication Oseltamivir (Tamiflu) Dosing Infection Control Issues Staff Exposure References Introduction This guideline
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationSetting The setting of the study was tertiary care (teaching hospitals). The study was conducted in Hong Kong.
Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess Ng F H, Wong W M, Wong B C, Kng C, Wong S Y, Lai K C, Cheng C S, Yuen W C, Lam S
More informationFACT SHEET FOR ADDITIONAL INFORMATION CONTACT
FACT SHEET FOR ADDITIONAL INFORMATION CONTACT Caroline Calderone Baisley, MPH, RS Michael S. Long, MS Director of Health Director of Environmental Services Tel. 203-622-7836 Tel: 203-622-7838 FREQUENTLY
More informationHerpes virus reactivation in the ICU. M. Ieven BVIKM
Herpes virus reactivation in the ICU M. Ieven BVIKM 07.04.2011 Introduction: Viruses identified in critically ill ICU patients Viral diseases have recently been the subject of numerous investigations in
More informationHepatitis E in South Africa. Tongai Maponga
Hepatitis E in South Africa Tongai Maponga 7th FIDSSA CONGRESS 2017 This is what usually comes to mind History of hepatitis E virus An ET-NANB hepatitis virus later named HEV was first suspected in 1980.
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationMiddle East Respiratory Syndrome Coronavirus
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 54 Middle East Respiratory Syndrome Coronavirus Author Ziad.A. Memish, MD, FRCPC, FACP Chapter Editor Michael Stevens, MD, MPH Topic Outline Topic outline
More informationCommunity-Acquired Pneumonia OBSOLETE 2
Community-Acquired Pneumonia OBSOLETE 2 Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with respect to appropriate
More informationclinical investigations in critical care The Role of Open-Lung Biopsy in ARDS*
clinical investigations in critical care The Role of Open-Lung Biopsy in ARDS* Sanjay R. Patel, MD; Dimitri Karmpaliotis, MD; Najib T. Ayas, MD; Eugene J. Mark, MD; John Wain, MD, FCCP; B. Taylor Thompson,
More informationEstimating RSV Disease Burden in the United States
Estimating RSV Disease Burden in the United States Brian Rha, MD, MSPH Medical Epidemiologist, Division of Viral Diseases Centers for Disease Control and Prevention Severe Acute Respiratory Infection Surveillance
More informationQuick Literature Searches
Quick Literature Searches National Pediatric Nighttime Curriculum Written by Leticia Shanley, MD, FAAP Institution: University of Texas Southwestern Medical Center Case 1 It s 1:00am and you have just
More informationMERS H7N9. coronavirus. influenza virus. MERS: Since September 2012: 160 cases, including 68 deaths (42%)
MERS coronavirus H7N9 influenza virus Marc Van Ranst, KU Leuven MERS: Since September 2012: 160 cases, including 68 deaths (42%) MERS coronavirus patient, 83 years, Saudi-Arabia H7N9: Since February 2013:
More informationAUTHORS: Romina D. Gerolaga, M.D.,* Robert Dennis Garcia, M.D.*
13 ORIGINAL ARTICLE A Case Control Study of the Demographic Characteristics, Risk Factors, Clinical Findings, Treatment and Outcome Among Children 18 Years and Below Who are Confirmed to have Influenza
More informationChapter 22. Pulmonary Infections
Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired
More informationHigh Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome
High Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome James C. Ho, Gaik C. Ooi, Thomas Y. Mok, Johnny W. Chan, Ivan Hung, Bing Lam, Poon C. Wong, Patrick C. Li, Pak
More information